Skip to main
ABT
ABT logo

Abbott Labs (ABT) Stock Forecast & Price Target

Abbott Labs (ABT) Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 47%
Buy 41%
Hold 12%
Sell 0%
Strong Sell 0%

Bulls say

Abbott Laboratories is projected to achieve organic sales growth of 6.0-7.0% by 2025, with current consensus estimates indicating a 6.4% year-over-year increase. Notable business segments, such as Electrophysiology and Structural Heart, have demonstrated strong organic growth of 13.7% and 11.3% year-over-year, respectively, bolstered by product launches and regulatory approvals in key markets. Abbott's robust balance sheet and a consistent history of increasing dividends for over 50 years further enhance its outlook, positioning the company favorably for future growth opportunities.

Bears say

Abbott Laboratories faces significant challenges that contribute to a negative outlook, primarily due to a substantial decline in Covid-19 testing revenue, which fell from $265 million in Q3'24 to $69 million in Q3'25, highlighting the ongoing impact of reduced testing demands. Additionally, the company is contending with greater macroeconomic pressures, including inflation and foreign exchange impacts, which further strain financial performance. The lagging sales in key markets, especially in diagnostics and the impact of funding cuts for HIV testing, compound these issues, leading to a mixed financial performance and a cautious view on future growth prospects.

Abbott Labs (ABT) has been analyzed by 17 analysts, with a consensus rating of Buy. 47% of analysts recommend a Strong Buy, 41% recommend Buy, 12% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Abbott Labs and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Abbott Labs (ABT) Forecast

Analysts have given Abbott Labs (ABT) a Buy based on their latest research and market trends.

According to 17 analysts, Abbott Labs (ABT) has a Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $146.53, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $146.53, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Abbott Labs (ABT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.